Oxford says TroVax trial will be different than Panvac-VF trial

By Elaine Rigoli

Tampa, Fla., July 31 - Oxford BioMedica plc said Monday that the failure of clinical trials of Panvac-VF, developed by Therion Biologics, does not mean that phase 3 trials of TroVax will not be successful.

The company noted that while Panvac-VF uses a similar viral delivery system to TroVax, the active antigenic components of TroVax are different to those used in Panvac-VF, which comprises CEA and Muc-1, whereas TroVax comprises Oxford's proprietary antigen, 5T4.

In addition, the Panvac-VF study was in pancreatic cancer patients who had already failed chemotherapy. This is a particularly challenging target where no product has shown a survival benefit, the company said in a news release.

The planned TroVax phase 3 Trist trial is in advanced renal cell cancer patients who will have received no prior therapy for their metastatic disease and who have a median survival, with current care, of about 12 months, the release said.

The company also said it is in active discussions with a number of potential commercial partners for TroVax but did not disclose names of potential partners.

Oxford is a biopharmaceutical company located in Oxford, England.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.